Additional 45,000 Doses of Oral Antiviral 'Paxlovid' Procured

Cumulative Prescriptions: 25,342 Patients

[Image source=Yonhap News]

[Asia Economy Reporter Ki Ha-young] An additional 45,000 doses of the oral COVID-19 treatment 'Paxlovid' have been imported into South Korea.

According to the Central Disease Control Headquarters on the 4th, 45,000 doses of Paxlovid were additionally imported on that day, bringing the total number of doses imported into the country to 118,000. As of 6:30 PM on the 3rd, the remaining stock in the country was 47,658 doses.

Since Paxlovid was first introduced in South Korea on January 14, a total of 25,342 patients have been prescribed the medication. Of these, 20,827 doses were administered to patients under home treatment, followed by 3,730 doses at infectious disease-dedicated hospitals, and 785 doses at residential treatment centers.

By region, the numbers are as follows: Gyeonggi 6,411, Seoul 4,488, Busan 3,259, Incheon 1,650, Daegu 1,596, Jeonbuk 1,178, Jeonnam 1,122, Gyeongbuk 1,103, Gyeongnam 1,029, Gangwon 650, Chungbuk 646, Daejeon 589, Gwangju 487, Ulsan 433, Chungnam 427, Jeju 162, and Sejong 112.

Currently, those eligible to receive Paxlovid include elderly individuals aged 60 and above, patients in their 40s and 50s with underlying conditions, immunocompromised individuals, patients in nursing hospitals and infectious disease-dedicated nursing hospitals, and inpatients at infectious disease-dedicated hospitals.

Meanwhile, as of midnight the previous day, the injectable COVID-19 treatment 'Remdesivir' was administered to 38,950 patients across 287 hospitals. The domestically developed antibody treatment 'Rekkirona Injection' was administered to 51,597 patients in 312 hospitals and other facilities.

This content was produced with the assistance of AI translation services.